<DOC>
	<DOC>NCT02980705</DOC>
	<brief_summary>This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.</brief_summary>
	<brief_title>Efficacy and Safety Study of SUNPG1622</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<criteria>Subject has provided informed written consent Subject is ≥ 18 years of age at time of Screening Subject must be on a stable dose of NSAID for ≥ 2 weeks prior to initiation of investigational product Subject has a negative test for TB within 4 weeks before initiating IMP Subjects with known diagnosis of fibromyalgia or complex regional pain syndromes Active uveitis or symptomatic inflammatory bowel disease requiring therapy at screening Radiographic evidence of total ankylosis of the spine Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>